Filing Flows › Carlsmed (CARL) › Guidance & outlook
Carlsmed (CARL) guidance and outlook
Carlsmed (CARL) reaffirmed its guidance on Sep 30, 2026: Revenue $74.0M–$78.0M for FY; Revenue +50% for FY.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY | $74.0M–$78.0M | reaffirmed |
| Revenue | FY | +50% | reaffirmed |
From the earnings release filed Sep 30, 2026 (8-K on EDGAR).
Carlsmed's latest quarter
Carlsmed, Q2 2026: revenue $18.9M (+57% year over year), operating margin -58.3%, net loss $10.5M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Carlsmed raise or lower its guidance?
Carlsmed (CARL) reaffirmed its guidance on Sep 30, 2026: Revenue $74.0M–$78.0M for FY; Revenue +50% for FY.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.